Wyeth-Ayerst Protonix I.V.
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The intravenous proton pump inhibitor pantoprazole will be launched in mid-April, according to the firm. Approved March 22, Protonix I.V. is indicated for "short-term treatment (seven to 10 days) of gastroesophageal reflux disease, as an alternative to oral therapy in patients who are unable to continue taking" oral Protonix. The tablet version of Protonix was launched in May last yea